ANI and SPI Guided Intraoperative Analgesia

September 28, 2019 updated by: Dostalova Vlasta, MD, PhD, University Hospital Hradec Kralove

ANI and SPI Guided Intraoperative Analgesia in Patients Undergoing Neurosurgical Procedures Under General Anaesthesia

There is accumulating evidence that inappropriate analgesia is asssociated with increasing risk of perioperative complications. The aim of the study is to compare intraoperative analgesia guided according to different methods of intraoperative analgesia monitoring, ANI and SPI respectively.

Study Overview

Detailed Description

The Surgical Pleth Index (SPI) and ANI (Analgesia Nociception Index) has been developed for monitoring of adequacy of analgesia during surgery.

The investigators want to compare anesthesiologist guided intraoperative analgesia with intraoperative analgesia guieded by ANI or SPI.

The following hypotheses have been made:

  1. Anesthesiologist guided analgesia will result in lower surgical stress
  2. Anesthesiologist guided analgesia will result in more hemodynamic stability and faster recovery of the patient after anesthesia

Study Type

Interventional

Enrollment (Actual)

72

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Hradec Kralove, Czechia, 50005
        • University hospital Hradec Králové

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients undergoing scheduled neurosurgical procedures under general anesthesia
  • GCS 15
  • ASA physical status I - III
  • elective procedures with estimated duration 1 - 3 hours

Exclusion Criteria:

  • Presence of non-sinus rhythm
  • pacemaker
  • planned postoperative ventilation
  • procedures with planned awake intervals
  • chronic pain with opioid medication
  • opioid addiction
  • epidural administration of local anaesthetic in combination with opioid
  • corticosteroid use
  • hormonal contraception
  • chronic respiratory disease with known respiratory failure

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Anesthesiologist quided analgesia
Sufentanil anesthesiologist analgesia is based on anesthesiologist decision.
Sufentanil is given based on the anesthesiologist decision in the sufentanil anesthesiologist analgesia group. Sufentanil is administered in 20 minute intervals in a standardized manner, the same dose as initially is given and flushed with 20 ml of saline. Indication for additional administration of opioid beyond this interval is 25 % increase of systemic arterial pressure over the baseline and/or 35% increase of heart rate over the baseline. The next dose of opioid can be given in the earliest after 3 minutes interval. The doses are repeated up to achievement of the haemodynamic stability. The last dose of opioid can be given no later than 15 minutes before the end of surgery.
Other Names:
  • Sufentanil, anesthesiologist
Experimental: ANI guided analgesia
Sufentanil ANI analgesia based on ANI analgesia monitor figures.
Sufentanil is given based on ANI analgesia monitor figures in the sufentanil ANI analgesia group. Targeted ANI range is 50 - 70. Figures lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially and flushed with 20 ml of saline. The next dose of opioid can be given in the earliest after 3 minutes interval, if indicated according to ANI monitoring. The doses are repeated up to achievement of the targeted range of analgesia (ANI). The last dose of opioid can be given no later than 15 minutes before the end of surgery.
Other Names:
  • Sufentanil, ANI
Experimental: SPI guided analgesia
Sufentanil SPI analgesia is based on the SPI analgesia monitor figures.
Sufentanil is given based on SPI value in the SPI guided analgesia group. The targer SPI range is set indiviudally based on the initial value of SPI recorded 5 minutes after the induction of anesthesia plus 10 points. In the ANI group, Sufentanil is given based on the ANI value, the target ANI range is 50 - 70. Values lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially. In the anesthesiologist guided analgesia group, Sufentanil is administered in a standardized manner.
Other Names:
  • Sufentanil, SPI

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cortisol serum level
Time Frame: End of surgery
nmol/l
End of surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to spontaneous ventilation
Time Frame: From the end of anesthesia up to two hours
min
From the end of anesthesia up to two hours
Time to extubation
Time Frame: From the end of anesthesia up to two hours
min
From the end of anesthesia up to two hours
Pain intensity at the time of departure from the operating theater
Time Frame: At the time of departure from the operating room, up to 30 min from the end of anesthesia
Assessment of pain using verbal pain scale (range 0-4)
At the time of departure from the operating room, up to 30 min from the end of anesthesia
Pain intensity at recovery room admission
Time Frame: At the time of ICU/recovery room admission, up to 15 minutes after ICU/recovery admission
Assessment of pain using verbal pain scale (range 0-4)
At the time of ICU/recovery room admission, up to 15 minutes after ICU/recovery admission
Mean pain intensity at the ICU/recovery room
Time Frame: From the admission to the ICU or recovery room up to 2 hours postoperatively
Mean value of pain intensity score using verbal pain scale (range 0-4)
From the admission to the ICU or recovery room up to 2 hours postoperatively
Postoperative respiratory complications
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Number of participants with postoperative respiratory complications
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
Sufentanil dose
Time Frame: From the beginning of anesthesia up to the end of anesthesia, an expacted average duration of 2 hours
microgramms per hour
From the beginning of anesthesia up to the end of anesthesia, an expacted average duration of 2 hours
Pain intensity
Time Frame: 1st postoperative day
Assessment of pain using verbal pain scale (range 0-4)
1st postoperative day
Pain intensity
Time Frame: 2nd postoperative day
Assessment of pain using verbal pain scale (range 0-4)
2nd postoperative day
Pain intensity
Time Frame: 3rd postoperative day
Assessment of pain using verbal pain scale (range 0-4)
3rd postoperative day
Number of doses of opioid analgesics
Time Frame: Until the end of the 3rd postoperative day
The total number of doses of opioid analgesics during the 3 postoperative days
Until the end of the 3rd postoperative day
Number of doses of non-opioid analgesics
Time Frame: Until the end of the 3rd postoperative day
The total number of doses of non-opioid analgesics during the 3 postoperative days
Until the end of the 3rd postoperative day
Time to achievement of normal end-tidal CO2 value
Time Frame: From the end of anesthesia up to two hours
min
From the end of anesthesia up to two hours
Length of postoperative hospital stay
Time Frame: From the day of surgery up to the end of hospital stay, an expected average of 2 weeks
days
From the day of surgery up to the end of hospital stay, an expected average of 2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2015

Primary Completion (Actual)

October 1, 2015

Study Completion (Actual)

November 1, 2015

Study Registration Dates

First Submitted

June 18, 2015

First Submitted That Met QC Criteria

July 1, 2015

First Posted (Estimate)

July 7, 2015

Study Record Updates

Last Update Posted (Actual)

October 1, 2019

Last Update Submitted That Met QC Criteria

September 28, 2019

Last Verified

September 1, 2019

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anesthesia

Clinical Trials on Sufentanil anesthesiologist analgesia

3
Subscribe